Cargando…

Real-world use of PCSK9 inhibitors: A single-center experience

OBJECTIVE: Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarsam, Sinan, Berry, Abeer, Degheim, George, Singh, Robby, Zughaib, Marcel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Clinical Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384467/ https://www.ncbi.nlm.nih.gov/pubmed/30280628 http://dx.doi.org/10.1177/0300060518800595

Ejemplares similares

False activation of the cardiac catheterization laboratory: The price to pay for shorter treatment delay
por: Degheim, George, et al.
Publicado: (2019)

Impact of CardioMEMS device placement on lifestyle modifications: a “pseudo-placebo” effect beyond the expected?
por: Assaad, Mahmoud, et al.
Publicado: (2018)

CardioMems® device implantation reduces repeat hospitalizations in heart failure patients: A single center experience
por: Assaad, Mahmoud, et al.
Publicado: (2019)

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
por: Chamberlain, Alanna M., et al.
Publicado: (2019)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

Appropriate Use of Transesophageal Echocardiogram for Infective Endocarditis: A Single Center Experience
por: Singh, Robby, et al.
Publicado: (2019)

Concomitant Wolff-Parkinson-White and Atrioventricular Nodal Reentrant Tachycardia: Which Pathway to Ablate?
por: Sarsam, Sinan, et al.
Publicado: (2015)

Early Detection of Subclinical Aortic Valve Endocarditis with the CardioMEMS Heart Failure System
por: Sarsam, Sinan, et al.
Publicado: (2017)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks
por: Hollstein, Tim, et al.
Publicado: (2020)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
por: Fischer, Laurenz T., et al.
Publicado: (2021)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Timeout for Contrast: Using Physician Behavior Modification to Reduce Contrast in the Catheterization Laboratory
por: Singh, Robby, et al.
Publicado: (2019)

Arteriolar vs. valvular thrombosis: Pick your evil!
por: Berry, Abeer, et al.
Publicado: (2018)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

Urban vs Suburban: Is the Door-to-Balloon Time Affected by Geographic, Socioeconomic, or Racial Differences? A Tale of Two Campuses
por: Zughaib, Marc, et al.
Publicado: (2020)

Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience
por: Scicali, Roberto, et al.
Publicado: (2020)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The Burden of Unnecessary Testing From a Regularly Ordered Laboratory Assay: Age-Adjusted d-Dimer Quality Improvement Study
por: Letourneau, Marcel M., et al.
Publicado: (2020)

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
por: Lin, Po-Lin, et al.
Publicado: (2023)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Wedged Sensor in Distress? Lessons Learned from Troubleshooting Dampened Transmitted PA Waveforms of CardioMEMS Device
por: Singh, Robby, et al.
Publicado: (2020)

Odynophagia after Cardiac Catheterization: A Rare Complication in the Presence of Aberrant Subclavian Artery
por: Naidu, Moumita, et al.
Publicado: (2020)

Dermatologic Conundrum: A Cardiac Condition Masqueraded as a Dermatologic Distraction
por: Degheim, George, et al.
Publicado: (2020)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Rapid resolution of left ventricular thrombus with apixaban therapy
por: Berry, Abeer, et al.
Publicado: (2017)

Transcervical Carotid Artery Stenting without Flow Reversal: A Report of Two Cases
por: Assaad, Mahmoud, et al.
Publicado: (2019)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
por: Seijas-Amigo, Jose, et al.
Publicado: (2023)

CardioMEMS in a Busy Cardiology Practice: Less than Optimal Implementation of a Valuable Tool to Reduce Heart Failure Readmissions
por: Singh, Robby, et al.
Publicado: (2018)

Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
por: Perrot, Nicolas, et al.
Publicado: (2020)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bl244efea29vo7l21t5oc128ms